1. Traffic control for your CNS

Galvani Bioelectronics. No, it is not Italian club music.  It’s the new company formed by Verily Life Sciences and pharma giant, GSK. Over the next few years they will invest nearly $700M USD to spearhead the bioelectronic medicine field. That’s a lot of money for a device projected to be smaller than a grain of rice. These miniature, implantable devices are designed to attach to individual nerves to first interpret then correct the irregular electrical signals caused by many chronic diseases. We’re not sure which will hurt more, the arthritis that caused you to get it or the shock you’ll feel every time it kicks in. Ok, we have no idea if it shocks you. Or if it hurts. But it probably does.

2. MedCity, a nice place to live

MedCity, in southeast London, is a collaboration between the mayor and the capital’s three academic health science centers – Imperial College Academic Health Science Centre, King’s Health Partners, and UCL Partners – and it just might be the future of healthcare. Significant changes to an industry typically come from the outside. The Dollar Shave Club was not started by Gillette, Uber was not a spin-off from a taxi company, and Kim Kardashian was…you get the point. MedCity is a collaboration, not a disruption. It is meeting in the middle and tackling clinical trial recruitment, bench research, market access, workspace/equipment, and fundraising/investment opportunities. The three most important words in healthcare might be: location, location, location.

3. Move over mAbs, stem cell therapies are (almost) here

Great news for individuals suffering from rheumatoid arthritis and not so great news for pharma companies holding patents on the monoclonal antibody-based biologics currently used to treat RA. An Australian biotech, Mesoblast, completed Phase II clinical trials on its stem cell treatment for rheumatoid arthritis to astounding results (some have inserted the word “cure” here). In a test designed to identify whether the stem cell treatment is efficient—by achieving 20% relief of signs and symptoms—researchers instead saw a 70% improvement among more than one-third of the patients who received MPC-300-IV. Since some RA patients are unable to take biologics, a stem cell therapy could benefit wider audiences.

4. Bad security is expensive

Leaving an unencrypted laptop containing more than 2,230 patient records in an unlocked vehicle overnight might be a bad idea. Even more so when it turns up stolen and your company is facing its third major security breach in a single year. According to the U.S. Department of Health and Human Services (HHS), “Demographic information, clinical information, health insurance information, patient names, addresses, credit card numbers and their expiration dates, and dates of birth” are some of the data stolen during three incidents for Advocate Health Care Network in 2013. Those mishaps have resulted in a $5.5 million settlement with the HHS, the largest data breach settlement ever. Advocate, however, reports that there have been no indications that the information has been misused… Yet. Yay?

5. No, Olympic swimmers aren’t covered in massive hickeys

Even though it seems like a reasonable explanation when you consider the 450,000 condoms being distributed within the Olympic village, instead, the splotches are the after-effect of the newest Olympic fad: cupping (yes we know, it even sounds gross). However the process itself is not a fad, it’s been done for at least 2,000 years along with other forms of traditional Chinese medicine like acupuncture. Similar to other forms of TCM, cupping doesn’t have a lot of rigorous clinical data to support it yet. The randomized clinical trials investigating cupping tend to have high risk of bias or small sample sizes, but according to those — and apparently Michael Phelps — it’s great for pain relief.